BBC News
watch One-Minute World News
Last Updated: Thursday, 16 June, 2005, 13:48 GMT 14:48 UK
Bristol-Myers in $300m settlement
A shareholder restitution fund has been set up
Bristol-Myers Squibb has two years to improve corporate governance
US drugs company Bristol-Myers Squibb has agreed to pay $300m (£165m) into a shareholders' fund, as prosecutors charged two former executives.

The firm and executives were accused of a practice called "channel stuffing" - offering incentives to get wholesalers to buy more of the company's products.

The scheme boosted earnings at the firm, which has now agreed a "deferred prosecution" with Newark lawmakers.

This means it avoids indictment, but must improve governance in two years.

Bristol-Myers Squibb will now set aside $249m in the second quarter towards the $300m for the shareholder restitution fund, after having initially set aside $51m in the first quarter.

"The government will not pursue its filed criminal complaint if it is satisfied after two years that the company has complied with all the terms of the agreement," Bristol-Myers said in a statement.

'Failed to disclose'

The firm must also endow a chair at Seton Hall University Law School in Newark specialising in teaching business ethics and corporate governance.

"This is a case where Bristol-Myers Squibb failed to disclose relevant information to its shareholders that would have affected its stock price," said Christopher J Christie, US Attorney for New Jersey.

It seems as if the company got off easy
Michael Krensavage, analyst at Raymond James & Associates

Meanwhile, the two former executives at the company were charged by federal prosecutors with securities fraud and conspiracy to commit securities fraud.

They are Frederick S Schiff, former chief financial officer, and Richard J Lane, former president of the company's medicines group.

If found guilty, the two face up to 10 years in prison and $1m in fines. Their lawyers said they were innocent and would be cleared at trial.

Board changes

Separately, the company's chairman Peter R Dolan has agreed to give up that position, but will remain as chief executive.

James D Robinson III, a board member since 1976, has been elected non-executive chairman.

However, not all observers were content with recent developments.

"It seems as if the company got off easy," Michael Krensavage, an analyst at Raymond James & Associates, told the Wall Street Journal.

"It's hard to see how stuffing $2.5bn in the channel is an accident... I still question whether the current management should be in charge."




SEE ALSO:
US drugs firm settles law suits
30 Jul 04 |  Business
Drugs giant restates earnings
10 Mar 03 |  Business
Bristol-Myers to redraft accounts
24 Oct 02 |  Business
US stocks stage late recovery
11 Jul 02 |  Business


RELATED INTERNET LINKS:
The BBC is not responsible for the content of external internet sites


PRODUCTS AND SERVICES

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia
UK | Business | Entertainment | Science/Nature | Technology | Health
Have Your Say | In Pictures | Week at a Glance | Country Profiles | In Depth | Programmes
Americas Africa Europe Middle East South Asia Asia Pacific